

## Evonik Financials & ESG KPIs

---

Financial KPIs Group	P. 2
ESG KPIs Group	P. 3
Division KPIs	P. 4-7
Group Income Statement	P. 8-9
Group Balance Sheet	P. 10
Group Cash Flow Statement	P. 11
Group Net Financial Position	P. 12
Definitions	P. 13

As of Q1 2025 (published May 12, 2025)

## Evonik Group Financials

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1
External Sales	12,199	14,955	18,488	15,267	3,796	3,930	3,832	3,599	15,157	3,777
Growth (%)	-7%	23%	24%	-17%	-5%	1%	2%	0%	-1%	-1%
Volumes (%)	-3%	11%	-4%	-8%	4%	5%	5%	4%	4%	2%
Prices (%)	-3%	12%	18%	-3%	-5%	-2%	0%	-2%	-2%	-2%
Exchange Rates (%)	-2%	-2%	5%	-2%	-1%	0%	-2%	0%	-1%	1%
Other (incl. M&A; %)	1%	2%	5%	-4%	-3%	-2%	-1%	-2%	-2%	-2%
Adjusted EBITDA	1,906	2,383	2,490	1,656	522	578	577	388	2,065	560
Margin (%)	15.6%	15.9%	13.5%	10.8%	13.8%	14.7%	15.1%	10.8%	13.6%	14.8%
EBIT	819	1,173	942	-243	252	93	322	-91	577	299
Adjusted EBIT	890	1,338	1,350	521	266	329	322	111	1,027	309
Margin (%)	7.3%	8.9%	7.3%	3.4%	7.0%	8.4%	8.4%	3.1%	6.8%	8.2%
Adjusted EPS	1.37	2.12	2.26	0.79	0.42	0.50	0.58	0.16	1.67	0.59
Free Cash Flow	780	950	785	801	127	217	357	172	873	195
Cash Conversion Rate <sup>1</sup>	41%	40%	32%	48%					42%	
Capex (Cash outflow for investment in intangible assets, pp&e)	956	865	865	793	251	143	180	266	840	190
Capital employed (annual average)	14,600	14,799	16,192	15,406					14,493	
ROCE (%)	6.1%	9.0%	8.3%	3.4%					7.1%	
Dividend (€)	1.15	1.17	1.17	1.17					1.17	
Employees (continuing operations)	33,106	33,004	34,029	33,409	33,090	32,757	32,040	31,930	31,930	31,585

<sup>1</sup> Free cash flow conversion = FCF / adj. EBITDA

## Evonik Group Environment, Social & Governance KPIs

Full set of ESG KPIs published separately on our IR website: [evonik.finance/investor-relations](https://evonik.finance/investor-relations)

	2020 FY	2021 FY	2022 FY	2023 FY	2024 FY
<b>Strategy &amp; Growth</b>					
Sales share with "Next Generation Solutions"	37%	41%	43%	43%	45%
<b>Governance &amp; Compliance</b>					
Training rate fighting money laundering	82%	96%	97%	98%	99%
Training rate antitrust law	88%	83%	85%	89%	90%
Training rate fighting corruption	88%	92%	91%	86%	95%
Training rate code of conduct	89%	89%	89%	92%	96%
Training rate Human Rights (new in 2024)				90%	84%
<b>Value Chain &amp; Products</b>					
Procurement volume (in € billion)	8.0	10.4	13.6	11.3	10.5
Production output (million metric tons)	8.9	9.5	8.4	7.5	7.3
Use of renewable raw materials in production	8.5%	9.7%	11.1%	12.0%	9.0%
Raw material suppliers covered by TfS assessments	73%	69%	66%	67%	71%
No. of sustainability audits (Evonik/TfS)	258	284	378	492	596
No. of sustainability assessments (Evonik/TfS)	1,148	1,345	1,545	1,296	1,309
R&D expenses (€ million)	433	464	461	443	459
<b>The environment</b>					
Scope 1 greenhouse gas emissions (thousands metric tons CO <sub>2</sub> )	4,860	4,381 <sup>a</sup>	4,221 <sup>a</sup>	3890 <sup>b</sup>	3,390
Scope 2 greenhouse gas emissions (thousands metric tons CO <sub>2</sub> )	571 <sup>b</sup>	1,916 <sup>a</sup>	1,757 <sup>a</sup>	1400 <sup>b</sup>	1,670
Scope 3 greenhouse gas emissions (million metric tons CO <sub>2</sub> )	20.0 <sup>b</sup>	23.4	20.5 <sup>a</sup>	18.9 <sup>b</sup>	21.6
% Reduction in greenhouse gas emissions Scope 1 & 2 (million metric tons CO <sub>2</sub> ) vs base year	-43	-43	-5 <sup>c</sup>	-15 <sup>c</sup>	-20
Total water intake (in million m <sup>3</sup> )	561.4	462 <sup>d</sup>	444 <sup>d</sup>	403	431
Specific water intake (in m <sup>3</sup> freshwater / metric ton production)	36.5	26.8 <sup>d</sup>	29.5 <sup>d</sup>	29.9	32.2
Production waste (thousand metric tons)	311	342 <sup>d</sup>	335 <sup>d</sup>	287	306
Specific production waste (in ton of waster per metric ton production)		0.036	0.04	0.038	0.042
<b>Employees</b>					
Early employee turnover	1.3%	2.2%	1.9%	2.2%	1.7%
Continuing professional development per employee (hours)	12	5	4	4	2
Women at level "Executives" (circle 1)	15.9%	17.7%	20.3%	22.2%	21.8%
Women at level "Senior management" (circle 2)	14.2%	17.6%	17.1%	18.5%	19.1%
Women in management (circle 3)	27.1%	28.7%	29.9%	30.3%	31.4%
Women in management (circles 1-3)	26.1%	27.9%	29.1%	29.6%	30.7%
<b>Safety</b>					
Occupational health performance index	5.4	5.6	5.5	5.5	5.5
Accident frequency rate (no. of accidents / working hours) <sup>b</sup>	0.16	0.19	0.25	0.21	0.14
Incident frequency rate (no. of accidents / working hours) <sup>b</sup>	1.45	0.48	0.49	0.43	0.44

a: adjusted figures corresponding to GHG Protocol Standards | b: Correction of data based on methodological improvements | c: for new target period 2021-2030 | d: data corrected for fast-close process

(for ESG KPI definitions please see separate "Definitions" page at the end of the file)

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1 <sup>1</sup>	2024 Q2 <sup>1</sup>	2024 Q3 <sup>1</sup>	2024 Q4 <sup>1</sup>	2024 FY <sup>1</sup>	2025 Q1
Sales	3,225	3,710	4,184	3,520	915	951	904	836	3,607	923
<i>Growth (%)</i>	-5%	15%	13%	-16%	-1%	4%	2%	2%	2%	1%
<i>Volumes (%)</i>	-3%	11%	-8%	-11%	5%	11%	8%	5%	7%	1%
<i>Prices (%)</i>	0%	5%	16%	0%	-5%	-6%	-4%	-3%	-5%	-1%
<i>Exchange Rates (%)</i>	-2%	-1%	4%	-3%	-1%	-1%	-2%	0%	0%	1%
<i>Other (incl. M&amp;A; %)</i>	0%	0%	1%	-2%	0%	0%	0%	0%	0%	0%
Adjusted EBITDA	857	920	946	673	200	230	218	130	779	201
<i>Margin (%)</i>	26.6%	24.8%	22.6%	19.1%	21.9%	24.2%	24.1%	15.6%	21.6%	21.8%
EBIT	683	739	782	481	148	180	169	77	575	150
Adjusted EBIT	681	739	753	489	148	180	169	77	575	150
<i>Margin (%)</i>	21.1%	19.9%	18.0%	13.9%	16.2%	18.9%	18.7%	9.2%	15.9%	16.3%
Capital expenditures	93	94	106	124	27	30	29	50	137	22
Capital employed (annual average)	4,244	4,168	4,631	4,403					4,405	
ROCE (%)	16.0%	17.7%	16.3%	11.1%					13.1%	
Employees	3,666	3,693	3,824	3,492	5,108	-	-	-	-	5,020

<sup>1</sup> Restated to reflect split of Technology & Infrastructure division into cross-site technology and site-specific infrastructure activities; smaller production sites, which often only serve one business line, have been allocated directly to the respective chemicals divisions  
 Volume and price split not restated

**Nutrition & Care**

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1 <sup>1</sup>	2024 Q2 <sup>1</sup>	2024 Q3 <sup>1</sup>	2024 Q4 <sup>1</sup>	2024 FY <sup>1</sup>	2025 Q1
Sales	2,992	3,557	4,237	3,611	900	905	996	962	3,764	1,007
<i>Growth (%)</i>	2%	19%	19%	-15%	2%	1%	8%	6%	4%	12%
<i>Volumes (%)</i>	2%	10%	-4%	-3%	2%	-5%	3%	3%	1%	11%
<i>Prices (%)</i>	4%	11%	16%	-6%	1%	5%	10%	3%	4%	-4%
<i>Exchange Rates (%)</i>	-4%	-2%	7%	-5%	-1%	1%	-5%	0%	-1%	1%
<i>Other (incl. M&amp;A; %)</i>	0%	0%	0%	-1%	0%	0%	0%	0%	0%	4%
Sales Animal Nutrition	1,474	1,789	2,192	1,750	483	450	512	489	1,934	554
Sales Health & Care	1,518	1,768	2,045	1,861	417	455	484	473	1,829	452
Adjusted EBITDA	560	717	677	389	146	144	198	128	616	197
<i>Margin (%)</i>	18.7%	20.2%	16.0%	10.8%	16.2%	15.9%	19.9%	13.3%	16.4%	19.6%
EBIT	285	404	396	-170	90	89	176	-37	318	140
Adjusted EBIT	301	453	405	147	91	89	142	60	382	142
<i>Margin (%)</i>	10.1%	12.7%	9.6%	4.1%	10.1%	9.8%	14.3%	6.2%	10.1%	14.1%
Capital expenditures	139	164	243	311	64	50	63	121	299	39
Capital employed (annual average)	3,914	3,893	4,286	3,970					3,912	
ROCE (%)	7.7%	11.6%	9.4%	3.7%					9.8%	
Employees	5,295	5,453	5,690	5,630	5,946	-	-	-	-	5,832

<sup>1</sup> Restated to reflect split of Technology & Infrastructure division into cross-site technology and site-specific infrastructure activities; smaller production sites, which often only serve one business line, have been allocated directly to the respective chemicals divisions  
 Volume and price split as well as sub division sales split not restated

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1 <sup>1</sup>	2024 Q2 <sup>1</sup>	2024 Q3 <sup>1</sup>	2024 Q4 <sup>1</sup>	2024 FY <sup>1</sup>	2025 Q1
Sales	3,235	3,918	5,240	4,461	1,094	1,149	1,099	1,114	4,455	1,098
<i>Growth (%)</i>	-4%	21%	23%	-15%	-8%	3%	0%	6%	0%	0%
<i>Volumes (%)</i>	-7%	16%	1%	-13%	0%	7%	2%	5%	3%	1%
<i>Prices (%)</i>	-1%	4%	18%	0%	-8%	-4%	0%	-1%	-3%	0%
<i>Exchange Rates (%)</i>	-2%	-2%	4%	-2%	-1%	0%	-2%	0%	-1%	1%
<i>Other (incl. M&amp;A; %)</i>	6%	3%	0%	0%	1%	0%	0%	2%	1%	-2%
Sales Inorganics	2,315	2,754	3,891	3,238	790	827	795	806	3,218	785
Sales Polymers	920	1,164	1,349	1,224	302	320	303	307	1,232	313
Adjusted EBITDA	529	650	743	540	160	173	167	106	607	149
<i>Margin (%)</i>	16.4%	16.6%	14.2%	12.1%	14.6%	15.1%	15.2%	9.5%	13.6%	13.6%
EBIT	226	346	405	57	74	92	83	-68	181	63
Adjusted EBIT	270	374	416	181	76	93	85	18	272	71
<i>Margin (%)</i>	8.3%	9.5%	7.9%	4.1%	6.9%	8.1%	7.7%	1.6%	6.1%	6.5%
Capital expenditures	466	379	266	236	38	45	56	103	242	45
Capital employed (annual average)	4,244	4,637	5,109	5,010					4,893	
ROCE (%)	6.4%	8.1%	8.1%	3.6%					5.6%	
Employees	7,874	7,742	8,011	8,103	8,670	-	-	-	-	8,361

<sup>1</sup> Restated to reflect split of Technology & Infrastructure division into cross-site technology and site-specific infrastructure activities; smaller production sites, which often only serve one business line, have been allocated directly to the respective chemicals divisions  
 Volume and price split as well as sub division sales split not restated

**Infrastructure / Other (including former Performance Materials division)**

<b>in € million</b>	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1 <sup>1</sup>	2024 Q2 <sup>1</sup>	2024 Q3 <sup>1</sup>	2024 Q4 <sup>1</sup>	2024 FY <sup>1</sup>	2025 Q1
Sales	2,747	3,771	4,827	3,675	887	925	833	687	3,331	749
Adjusted EBITDA	-40	96	124	54	16	31	-6	24	63	13
EBIT	-375	-316	-641	-611	-59	-268	-107	-62	-496	-54
Adjusted EBIT	-362	-228	-224	-296	-49	-33	-74	-44	-202	-54
Capital expenditures	297	292	241	189	28	23	32	57	138	27
Employees	16,271	16,116	16,504	16,184	12,319	-	-	-	-	12,372

<sup>1</sup> Restated to reflect split of Technology & Infrastructure division into cross-site technology and site-specific infrastructure activities; smaller production sites, which often only serve one business line, have been allocated directly to the respective chemicals divisions

## Group Income Statement

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1
Sales	12,199	14,955	18,488	15,267	3,796	3,930	3,832	3,599	15,157	3,777
Cost of sales	-8,865	-10,925	-14,257	-12,567	-2,795	-2,885	-2,804	-2,935	-11,419	-2,769
<b>Gross profit on sales</b>	<b>3,334</b>	<b>4,030</b>	<b>4,231</b>	<b>2,700</b>	<b>1,001</b>	<b>1,045</b>	<b>1,028</b>	<b>664</b>	<b>3,738</b>	<b>1,008</b>
Selling expenses	-1,501	-1,717	-2,035	-1,836	-473	-473	-468	-479	-1,894	-454
Research and development expenses	-433	-464	-460	-443	-111	-109	-106	-133	-459	-106
General administrative expenses	-531	-546	-554	-488	-129	-353	-128	-129	-740	-126
Other operating income & expenses	-65	-138	-252	-186	-38	-22	-7	-24	-89	-25
Result from investments recognized at equity	15	8	12	10	2	5	3	10	21	2
<b>Income before financial result and income taxes, cont. ops. = EBIT</b>	<b>819</b>	<b>1,173</b>	<b>942</b>	<b>-243</b>	<b>252</b>	<b>93</b>	<b>322</b>	<b>-91</b>	<b>577</b>	<b>299</b>
Financial Result	-135	-88	-19	-108	-33	-31	-48	-30	-143	-29
<b>Income before income taxes, continuing operations</b>	<b>684</b>	<b>1,085</b>	<b>923</b>	<b>-351</b>	<b>219</b>	<b>62</b>	<b>274</b>	<b>-121</b>	<b>434</b>	<b>270</b>
Income taxes	-181	-316	-369	-101	-59	-61	-47	-28	-194	-34
<b>Income after taxes, continuing operations</b>	<b>503</b>	<b>769</b>	<b>554</b>	<b>-452</b>	<b>160</b>	<b>1</b>	<b>227</b>	<b>-149</b>	<b>240</b>	<b>236</b>
Income after taxes, discontinued operations	-24	-2	1	-	0	0	0	1	0	0
<b>Income after taxes</b>	<b>479</b>	<b>767</b>	<b>555</b>	<b>-452</b>	<b>160</b>	<b>1</b>	<b>227</b>	<b>-148</b>	<b>240</b>	<b>236</b>
thereof attributable to non-controlling interests	14	21	15	13	4	6	4	4	18	3
<b>Shareholders of EVONIK Industries AG (net income)</b>	<b>465</b>	<b>746</b>	<b>540</b>	<b>-465</b>	<b>156</b>	<b>-5</b>	<b>223</b>	<b>-152</b>	<b>222</b>	<b>233</b>
<b>EPS</b>	<b>1.00</b>	<b>1.60</b>	<b>1.16</b>	<b>-1.00</b>	<b>0.33</b>	<b>-0.01</b>	<b>0.48</b>	<b>-0.32</b>	<b>0.48</b>	<b>0.50</b>

## Group Adjusted Income Statement

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1
<b>Sales</b>	<b>12,199</b>	<b>14,955</b>	<b>18,488</b>	<b>15,267</b>	<b>3,796</b>	<b>3,930</b>	<b>3,832</b>	<b>3,599</b>	<b>15,157</b>	<b>3,777</b>
<b>Adjusted EBITDA</b>	<b>1,906</b>	<b>2,383</b>	<b>2,490</b>	<b>1,656</b>	<b>522</b>	<b>578</b>	<b>577</b>	<b>388</b>	<b>2,065</b>	<b>560</b>
Adjusted depreciation and amortization	-1,016	-1,045	-1,140	-1,135	-256	-249	-255	-278	-1,038	-251
<b>Adjusted EBIT</b>	<b>890</b>	<b>1,338</b>	<b>1,350</b>	<b>521</b>	<b>266</b>	<b>329</b>	<b>322</b>	<b>110</b>	<b>1,027</b>	<b>309</b>
Adjusted net financial result	-146	-97	-19	-103	-33	-31	-48	-31	-143	-29
Adjusted depreciation and amortization on intangible assets	149	162	169	153	35	35	34	40	144	34
<b>Adjusted income before income taxes, continuing operations</b>	<b>893</b>	<b>1,403</b>	<b>1,500</b>	<b>571</b>	<b>268</b>	<b>333</b>	<b>308</b>	<b>119</b>	<b>1,028</b>	<b>314</b>
Adjusted income taxes, continuing operations	-239	-396	-431	-188	-67	-93	-33	-40	-233	-36
<b>Adjusted income after taxes</b>	<b>654</b>	<b>1,007</b>	<b>1,069</b>	<b>383</b>	<b>201</b>	<b>240</b>	<b>275</b>	<b>79</b>	<b>795</b>	<b>278</b>
Adjusted non-controlling interest	-14	-21	-15	-13	-4	-6	-4	-4	-18	-3
<b>Adjusted net income</b>	<b>640</b>	<b>986</b>	<b>1,054</b>	<b>370</b>	<b>197</b>	<b>234</b>	<b>271</b>	<b>74</b>	<b>777</b>	<b>275</b>
<b>Adjusted EPS</b>	<b>1.37</b>	<b>2.12</b>	<b>2.26</b>	<b>0.79</b>	<b>0.42</b>	<b>0.50</b>	<b>0.58</b>	<b>0.16</b>	<b>1.67</b>	<b>0.59</b>

## Adjustments

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1
Restructuring measures	-31	-32	-121	-64	-2	-228	-2	-173	-405	-12
Acquisitions and divestments	-40	-29	40	-237	-11	-2	-18	-3	-34	-11
Other special items	0	-104	-327	-463	-1	-6	20	-24	-11	13
<b>= Adjustments</b>	<b>-71</b>	<b>-165</b>	<b>-408</b>	<b>-764</b>	<b>-14</b>	<b>-236</b>	<b>0</b>	<b>-200</b>	<b>-450</b>	<b>-10</b>

Adjustment categories changed as of December 31, 2023 to avoid overlaps between categories; prior year figures restated

## Group Balance Sheet

### Assets

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY	2025 Q1
Intangible assets	5,877	6,045	5,710	5,525	5,556	5,552	5,417	5,571	5,426
Property, plant and equipment	6,588	6,963	6,962	6,294	6,320	6,307	6,270	6,450	6,305
Right of use assets (capitalized leasing)	668	608	972	965	940	928	903	947	905
Investments recognized at equity	75	81	88	52	44	40	43	49	51
Financial assets	607	581	441	460	445	444	509	467	424
Deferred tax assets	2,004	1,755	890	642	672	678	677	664	629
Other income tax assets	13	16	19	20	21	22	21	25	24
Other non-financial assets	102	125	64	78	77	58	59	69	110
<b>Non-current assets</b>	<b>15,934</b>	<b>16,174</b>	<b>15,146</b>	<b>14,036</b>	<b>14,075</b>	<b>14,029</b>	<b>13,899</b>	<b>14,242</b>	<b>13,874</b>
Inventories	1,806	2,548	2,820	2,349		2,599	2,658	2,662	2,751
Other income tax assets	211	199	98	209	189	179	122	166	138
Trade accounts receivable	1,455	1,954	1,898	1,607		1,813	1,706	1,622	1,732
Other non-financial assets	231	382	517	373	407	462	433	381	440
Financial assets	697	571	610	381	371	342	284	216	574
Cash and cash equivalents	563	456	645	749	794	521	460	461	733
<b>Current assets</b>	<b>4,963</b>	<b>6,110</b>	<b>6,588</b>	<b>5,668</b>	<b>6,109</b>	<b>5,916</b>	<b>5,663</b>	<b>5,508</b>	<b>6,368</b>
Assets held for sale	0	0	76	236	264	261	0	0	0
<b>Current assets</b>	<b>4,963</b>	<b>6,110</b>	<b>6,664</b>	<b>5,904</b>	<b>6,373</b>	<b>6,177</b>	<b>5,663</b>	<b>5,508</b>	<b>6,368</b>
<b>Total assets</b>	<b>20,897</b>	<b>22,284</b>	<b>21,810</b>	<b>19,940</b>	<b>20,448</b>	<b>20,206</b>	<b>19,562</b>	<b>19,750</b>	<b>20,242</b>

### Liabilities

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY	2025 Q1
Issued capital	466	466	466	466	466	466	466	466	466
Reserves	7,546	8,823	10,508	8,444	8,672	8,401	8,552	8,554	8,719
<b>Equity attributable to shareholders of Evonik Industries AG</b>	<b>8,012</b>	<b>9,289</b>	<b>10,974</b>	<b>8,910</b>	<b>9,138</b>	<b>8,867</b>	<b>9,018</b>	<b>9,020</b>	<b>9,185</b>
Equity attributable to non-controlling interests	87	83	82	76	78	71	77	80	82
<b>Total equity</b>	<b>8,099</b>	<b>9,372</b>	<b>11,056</b>	<b>8,986</b>	<b>9,216</b>	<b>8,938</b>	<b>9,095</b>	<b>9,100</b>	<b>9,267</b>
Provisions for pensions and other post-employment benefits	4,618	3,766	1,359	1,858	1,828	1,575	1,564	1,662	1,449
Other provisions	715	657	542	517	520	688	681	734	734
Deferred tax liabilities	586	628	661	608	613	630	614	638	633
Other income tax liabilities	275	195	246	268	273	271	266	254	258
Financial liabilities	3,564	3,531	4,117	3,502	3,519	3,485	3,135	3,162	3,629
Other payables	114	143	182	153	139	129	130	141	97
<b>Non-current liabilities</b>	<b>9,872</b>	<b>8,920</b>	<b>7,107</b>	<b>6,906</b>	<b>6,892</b>	<b>6,778</b>	<b>6,390</b>	<b>6,591</b>	<b>6,800</b>
Other provisions	744	892	732	606	681	711	833	923	955
Other income tax liabilities	136	211	189	124	152	151	111	87	86
Financial liabilities	434	477	429	1,153	1,130	1,205	1,083	1,034	941
Trade accounts payable	1,273	2,022	1,735	1,521	1,675	1,682	1,511	1,600	1,702
Other payables	339	390	501	457	485	535	539	415	491
<b>Current liabilities</b>	<b>2,926</b>	<b>3,992</b>	<b>3,586</b>	<b>3,861</b>	<b>4,123</b>	<b>4,284</b>	<b>4,077</b>	<b>4,059</b>	<b>4,175</b>
Liabilities associated with assets held for sale	0	0	61	187	217	206	0	0	0
<b>Current liabilities</b>	<b>2,926</b>	<b>3,992</b>	<b>3,647</b>	<b>4,048</b>	<b>4,340</b>	<b>4,490</b>	<b>4,077</b>	<b>4,059</b>	<b>4,175</b>
<b>Total equity and liabilities</b>	<b>20,897</b>	<b>22,284</b>	<b>21,810</b>	<b>19,940</b>	<b>20,448</b>	<b>20,206</b>	<b>19,562</b>	<b>19,750</b>	<b>20,242</b>

## Group Cash Flow Statement

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1
Income before financial result and income taxes, continuing operations = EBIT	819	1,173	942	-243	252	93	321	-90	577	299
Depreciation, amortization, impairment losses/reversal of impairment losses or	1,018	1,073	1,568	1,841	265	250	234	368	1,117	240
Result from investments recognized at equity	-15	-8	-12	-10	-2	-6	-3	-10	-21	-2
Gains/losses on disposal of non current assets	-10	43	-50	-1	-3	-1	21	5	22	15
Change in inventories	70	-675	-270	310	-218	-34	-99	54	-297	-140
Change in trade accounts receivable	54	-449	42	105	-180	-35	118	118	21	-143
Change in trade accounts payable and current advance payments received fro	-30	680	-257	-157	261	-11	-180	4	74	185
Change in provisions for pensions and other post-employment benefits	-14	83	-19	-55	-31	-13	0	-4	-48	-4
Change in other provisions	-133	207	-149	-141	76	192	126	141	535	37
Change in miscellaneous assets/liabilities	33	-23	10	152	-28	-23	16	-45	-81	-100
Cash inflows from dividends	27	19	19	25	-	20	1	6	27	0
Tax payments relating to carve-out of the methacrylates business	-	-	-	-	-	-	-	-	-	-
Cash inflows/outflows for income taxes	-83	-308	-174	-232	-14	-72	-18	-109	-213	-2
<b>Cash flow from operating activities, continuing operations</b>	<b>1,736</b>	<b>1,815</b>	<b>1,650</b>	<b>1,594</b>	<b>378</b>	<b>360</b>	<b>537</b>	<b>438</b>	<b>1,713</b>	<b>385</b>
Cash flow from operating activities, discontinued operations	-9	0	0	0	0	0	0	0	0	0
<b>Cash flow from operating activities</b>	<b>1,727</b>	<b>1,815</b>	<b>1,650</b>	<b>1,594</b>	<b>378</b>	<b>360</b>	<b>537</b>	<b>438</b>	<b>1,713</b>	<b>385</b>
Cash outflows for investments in intangible assets, property, plant and equipm	-956	-865	-865	-793	-251	-143	-180	-266	-840	-190
Cash outflows for investments in shareholdings	-474	-85	-27	-76	-3	-4	-14	0	-15	0
Cash outflows for loss from divestments of shareholdings	-	-145	97	-32	-13	0	0	0	-13	0
Cash outflows from divestments of businesses and other shareholdings	-	-21	-	-5	-	0	0	0	-6	0
Cash inflows from divestments of intangible assets, property, plant and equipm	45	9	5	15	16	3	-5	7	21	8
Cash inflows for loss from divestments of shareholdings	65	2	-	43	-	3	17	-4	16	3
Cash inflows for investments in shareholdings	-	-	-	2	-	-	-	0	0	0
Cash inflows/outflows relating to securities, deposits and loans	720	23	-3	161	-13	14	85	52	137	-352
Cash inflows from interest	30	12	16	32	12	8	11	6	37	20
<b>Cash flow from investing activities, continuing operations</b>	<b>-570</b>	<b>-1,070</b>	<b>-777</b>	<b>-653</b>	<b>-252</b>	<b>-119</b>	<b>-86</b>	<b>-205</b>	<b>-663</b>	<b>-509</b>
Cash flow from investing activities, discontinued operations	0	0	0	0	0	0	0	0	0	0
<b>Cash flow from investing activities</b>	<b>-570</b>	<b>-1,070</b>	<b>-777</b>	<b>-653</b>	<b>-252</b>	<b>-119</b>	<b>-86</b>	<b>-205</b>	<b>-663</b>	<b>-509</b>
Cash inflows/outflows relating to capital contributions	2	0	0	0	0	0	0	0	0	1
Cash outflows for dividends to shareholders of Evonik Industries AG	-536	-536	-545	-545	0	-545	0	0	-545	1
Cash outflows for dividends to non-controlling interests	-16	-21	-13	-10	-4	-12	0	-4	-20	-1
Cash inflows/outflows from changes in ownership interests in subsidiaries withc	0	0	-5	-	-	0	0	-	0	0
Cash outflows for the purchase of treasury shares	-16	-15	-16	-16	-12	0	-10	0	-12	0
Cash inflows from the sale of treasury shares	12	12	12	12	-	9	0	0	9	0
Cash inflows from the addition of financial liabilities	1,039	655	1,649	716	19	134	487	68	708	521
Cash outflows for repayment of financial liabilities	-2,156	-948	-1,577	-893	-82	-65	-946	-261	-1,354	-107
Cash inflows/outflows in connection with financial transactions	14	91	-104	12	11	-16	7	-8	-7	0
Cash outflows for interest	-77	-94	-73	-99	-17	-15	-52	-25	-109	-14
<b>Cash flow from financing activities, continuing operations</b>	<b>-1,734</b>	<b>-856</b>	<b>-672</b>	<b>-823</b>	<b>-85</b>	<b>-510</b>	<b>-504</b>	<b>-230</b>	<b>-1,330</b>	<b>400</b>
Cash flow from financing activities, discontinued operations	0	0	0	0	0	0	0	0	0	0
<b>Cash flow from financing activities</b>	<b>-1,734</b>	<b>-856</b>	<b>-672</b>	<b>-823</b>	<b>-85</b>	<b>-510</b>	<b>-504</b>	<b>-230</b>	<b>-1,330</b>	<b>400</b>
<b>Change in cash and cash equivalents</b>	<b>-577</b>	<b>-111</b>	<b>201</b>	<b>118</b>	<b>41</b>	<b>-269</b>	<b>-53</b>	<b>1</b>	<b>-280</b>	<b>276</b>
<b>Cash and cash equivalents as of beginning of period</b>	<b>1,165</b>	<b>563</b>	<b>456</b>	<b>645</b>	<b>749</b>	<b>794</b>	<b>519</b>	<b>460</b>	<b>749</b>	<b>460</b>
Change in cash and cash equivalents	-577	-111	201	118	41	-269	-53	3	-280	276
Changes in exchange rates and other changes in cash and cash equivalents	-25	4	-12	-14	4	-4	-7	-2	-8	-3
<b>Cash and cash equivalents as of end of period</b>	<b>563</b>	<b>456</b>	<b>645</b>	<b>749</b>	<b>794</b>	<b>521</b>	<b>459</b>	<b>461</b>	<b>461</b>	<b>733</b>
Cash and cash equivalents included in assets held for sale	0	0	0	0	0	0	0	0	0	0
<b>Cash and cash equivalents as on the balance sheet as of end of period</b>	<b>563</b>	<b>456</b>	<b>645</b>	<b>749</b>	<b>794</b>	<b>521</b>	<b>459</b>	<b>461</b>	<b>461</b>	<b>733</b>

## Group Net Financial Position

in € million	2020 FY	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY	2025 Q1
Non-current financial liabilities	-3,564	-3,527	-4,074	-3,320	-3,302	-3,288	-2,955	-2,961	-3,429
Current financial liabilities	-368	-232	-243	-1,006	-979	-1,105	-971	-883	-845
<b>Financial debt</b>	<b>-3,932</b>	<b>-3,759</b>	<b>-4,317</b>	<b>-4,326</b>	<b>-4,281</b>	<b>-4,393</b>	<b>-3,926</b>	<b>-3,844</b>	<b>-4,274</b>
- Cash and cash equivalents	563	456	645	749	794	521	460	461	733
- Current securities	466	446	413	261	269	259	176	128	482
- Other financial assets	17	0	2	6	6	2	4	2	1
<b>Financial assets</b>	<b>1,046</b>	<b>902</b>	<b>1,060</b>	<b>1,016</b>	<b>1,069</b>	<b>782</b>	<b>640</b>	<b>591</b>	<b>1,216</b>
<b>Net financial debt/cash as stated on the balance sheet</b>	<b>-2,886</b>	<b>-2,857</b>	<b>-3,257</b>	<b>-3,310</b>	<b>-3,212</b>	<b>-3,611</b>	<b>-3,286</b>	<b>-3,253</b>	<b>-3,058</b>
<b>Net financial debt/cash, discontinued operations</b>	-	-	-	-	-	0	0	0	0
<b>Net financial debt/cash including discontinued operations</b>	<b>-2,886</b>	<b>-2,857</b>	<b>-3,257</b>	<b>-3,310</b>	<b>-3,212</b>	<b>-3,611</b>	<b>-3,286</b>	<b>-3,253</b>	<b>-3,058</b>

## Financial KPI Definitions

<b>Adjusted EBIT</b>	Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets.
<b>Adjusted EBITDA</b>	Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors.
<b>Adjusted net income</b>	We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items.
<b>Adjustments</b>	Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business.
<b>Free Cash Flow</b>	The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment.
<b>ROCE</b>	The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period.

## ESG KPI Definitions

<b>Value added in € million</b>	We use an impact valuation to regularly measure and analyze the direct and indirect impacts from an economic, ecological, and social perspective. This supplements our established analytical approaches. We anticipate that this will allow early identification of potential future opportunities and risks, make our business model more resilient, and improve understanding of the long-term value that our business activities create for society. We aim to assign a monetary value to individual indicators such as continuing development of employees, employment impacts, and global warming so they can be compared. Most of the factors used for this are publicly available.
<b>Sales share with "Next Generation Solutions"</b>	Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA) For more information please see Evonik website: Responsibility - Value Chain & Products - Sustainability Analysis
<b>Internal Investigations</b>	Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included.
<b>Disciplinary Measures</b>	Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated.
<b>Raw Material Suppliers Covered by TFS Assessments</b>	This number indicates how many raw material suppliers have been covered by TFS assessments in that year. The chemical industry set up the Together for Sustainability (TFS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative.
<b>Greenhouse Gas Emissions</b>	Scope 1: Evonik's direct energy and process-related emissions; Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach); Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, energy requirements for offices and emissions from the disposal and recycling of products sold.
<b>Early Employee Turnover</b>	Turnover of newly hired employees within the first year of employment
<b>Management circles/ levels</b>	Management circle 1 = executive functions, i.e., top management functions in the Evonik Group Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions Management circle 3 = further management functions
<b>Occupational Health Performance Index</b>	This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually.
<b>Specific water intake</b> <small>in m<sup>3</sup> freshwater per metric ton production</small>	Freshwater usage in relation to production.
<b>Total water intake</b>	Evonik's consumption of freshwater is the total of drinking water, groundwater, surface water, and recycled water. Total water intake is the sum of total freshwater and salt water (sea water).